FDA approves Johnson & Johnson’s nasal spray for depression
FDA approves standalone use of J&J’s ketamine-derived depression treatment
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company said on Tuesday.
Johnson & Johnson has secured FDA approval for expanded use of its Spravato nasal spray, now cleared as a standalone ...
Johnson & Johnson is set to report earnings before the bell Wednesday, with analysts expecting revenue and profit growth from ...
In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report), with a ...
Johnson & Johnson is one of several Dow Jones Industrial Average stocks reporting financial results this week. A look at the ...
J&J on Tuesday said the green light makes Spravato the first and only monotherapy for adults with major depressive disorder who have had an inadequate response to at least two oral antidepressants.
Barclays lowered the firm’s price target on Johnson & Johnson to $159 from $160 and keeps an Equal Weight rating on the shares. The firm ...
Staying ahead of the competition is critical in every sector, particularly in the dynamic healthcare space, where a single ...
We recently published an article titled Jim Cramer Discussed 9 Stocks for This Week’s Game Plan. In this article, we are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback